Information on cost reimbursement through mandatory basic health insurance
Since 2017, pharmacogenetic analyses are included in the Federal list of analyses, which specifies tariffs for laboratory analyses and the terms under which the costs of analyses are covered by the Swiss mandatory basic health insurance. With their addition to this list, the costs of pharmacogenetic tests are now covered through the compulsory health insurance in cases where certain limitations are met.
Specifically, these limitations include:
In addition, there are important limitations regarding the prescription of pharmacogenetic tests:
The current version of the SSCPT list of gene-drug pairs can be accessed here: www.bag.admin.ch/ref
For tests, which require prescription by a specialist in clinical pharmacology and toxicology, clinical pharmacology consultation services are available in all regions of Switzerland. A list with contact information can be found under the following link: https://naturwissenschaften.ch/organisations/sscpt/activities/clinical_consultations
Pharmacogenetic tests are genetic analyses and therefore fall under the Federal Act on Human Genetic Testing (LAGH – GUMG SR 810.12). As such, pharmacogenetic tests may not be performed unless the person concerned has been provided with adequate information about the test and has given his or her voluntary consent.
To ensure compliance with this law, laboratories performing pharmacogenetic tests require a written consent signed by the patient along with the test order. In addition to providing the consent itself, this form also allows the patient to specify whether or not any remaining biological material (i.e. blood, DNA) should be stored for any potential future analyses, and whether it may be used for quality testing or research purposes.
A template for patient information about pharmacogenetic testing and a consent form for pharmacogenetic tests can be downloaded here: